140 related articles for article (PubMed ID: 31160176)
21. Discovery of a compound that acts as a bacterial PyrG (CTP synthase) inhibitor.
Yoshida T; Nasu H; Namba E; Ubukata O; Yamashita M
J Med Microbiol; 2012 Sep; 61(Pt 9):1280-1285. PubMed ID: 22700553
[TBL] [Abstract][Full Text] [Related]
22. Structure--activity relationships of the peptide deformylase inhibitor BB-3497: modification of the P2' and P3' side chains.
Davies SJ; Ayscough AP; Beckett RP; Clements JM; Doel S; Pratt LM; Spavold ZM; Thomas SW; Whittaker M
Bioorg Med Chem Lett; 2003 Aug; 13(16):2715-8. PubMed ID: 12873500
[TBL] [Abstract][Full Text] [Related]
23. Antimicrobial activity of the new macrolide flurithromycin against Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Branhamella catarrhalis and Staphylococcus aureus.
Nord CE; Lindmark A; Persson I
J Chemother; 1989 Jul; 1(4 Suppl):203-4. PubMed ID: 16312369
[No Abstract] [Full Text] [Related]
24. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).
Miller WH; Seefeld MA; Newlander KA; Uzinskas IN; Burgess WJ; Heerding DA; Yuan CC; Head MS; Payne DJ; Rittenhouse SF; Moore TD; Pearson SC; Berry V; DeWolf WE; Keller PM; Polizzi BJ; Qiu X; Janson CA; Huffman WF
J Med Chem; 2002 Jul; 45(15):3246-56. PubMed ID: 12109908
[TBL] [Abstract][Full Text] [Related]
25. Peptide deformylase as an antibacterial drug target: target validation and resistance development.
Apfel CM; Locher H; Evers S; Takács B; Hubschwerlen C; Pirson W; Page MG; Keck W
Antimicrob Agents Chemother; 2001 Apr; 45(4):1058-64. PubMed ID: 11257016
[TBL] [Abstract][Full Text] [Related]
26. Discovery of bacterial NAD+-dependent DNA ligase inhibitors: optimization of antibacterial activity.
Stokes SS; Huynh H; Gowravaram M; Albert R; Cavero-Tomas M; Chen B; Harang J; Loch JT; Lu M; Mullen GB; Zhao S; Liu CF; Mills SD
Bioorg Med Chem Lett; 2011 Aug; 21(15):4556-60. PubMed ID: 21719282
[TBL] [Abstract][Full Text] [Related]
27. Isoxazole-3-hydroxamic acid derivatives as peptide deformylase inhibitors and potential antibacterial agents.
Calí P; Naerum L; Mukhija S; Hjelmencrantz A
Bioorg Med Chem Lett; 2004 Dec; 14(24):5997-6000. PubMed ID: 15546716
[TBL] [Abstract][Full Text] [Related]
28. Quality control guidelines for MIC susceptibility testing of NVP PDF-713: a novel peptide deformylase inhibitor.
Anderegg TR; Biedenbach DJ; Jones RN;
Int J Antimicrob Agents; 2003 Jul; 22(1):84-6. PubMed ID: 12842335
[No Abstract] [Full Text] [Related]
29. Synthesis and antibacterial activity of peptide deformylase inhibitors.
Huntington KM; Yi T; Wei Y; Pei D
Biochemistry; 2000 Apr; 39(15):4543-51. PubMed ID: 10758004
[TBL] [Abstract][Full Text] [Related]
30. N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity.
Hackbarth CJ; Chen DZ; Lewis JG; Clark K; Mangold JB; Cramer JA; Margolis PS; Wang W; Koehn J; Wu C; Lopez S; Withers G; Gu H; Dunn E; Kulathila R; Pan SH; Porter WL; Jacobs J; Trias J; Patel DV; Weidmann B; White RJ; Yuan Z
Antimicrob Agents Chemother; 2002 Sep; 46(9):2752-64. PubMed ID: 12183225
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and evaluation of second generation MurF inhibitors based on a cyanothiophene scaffold.
Hrast M; Anderluh M; Knez D; Randall CP; Barreteau H; O'Neill AJ; Blanot D; Gobec S
Eur J Med Chem; 2014 Feb; 73():83-96. PubMed ID: 24384549
[TBL] [Abstract][Full Text] [Related]
32. Discovery of benzhydrol-oxaborole derivatives as Streptococcus pneumoniae leucyl-tRNA synthetase inhibitors.
Hao G; Li H; Yang F; Dong D; Li Z; Ding Y; Pan W; Wang E; Liu R; Zhou H
Bioorg Med Chem; 2021 Jan; 29():115871. PubMed ID: 33221064
[TBL] [Abstract][Full Text] [Related]
33. Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM 415), a novel inhibitor of bacterial peptide deformylase.
Fritsche TR; Moet GJ; Jones RN
Clin Microbiol Infect; 2004 Sep; 10(9):857-60. PubMed ID: 15355422
[TBL] [Abstract][Full Text] [Related]
34. Stereochemical definition and chirospecific synthesis of the peptide deformylase inhibitor Sch 382583.
Coats RA; Lee SL; Davis KA; Patel KM; Rhoads EK; Howard MH
J Org Chem; 2004 Mar; 69(5):1734-7. PubMed ID: 14987037
[TBL] [Abstract][Full Text] [Related]
35. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
36. Biphenyl tetrazole-thiazolidinediones as novel bacterial peptide deformylase inhibitors: Synthesis, biological evaluations and molecular docking study.
Khan FAK; Jadhav KS; Patil RH; Shinde DB; Arote RB; Sangshetti JN
Biomed Pharmacother; 2016 Oct; 83():1146-1153. PubMed ID: 27551762
[TBL] [Abstract][Full Text] [Related]
37. Identification of novel potent bicyclic peptide deformylase inhibitors.
Molteni V; He X; Nabakka J; Yang K; Kreusch A; Gordon P; Bursulaya B; Warner I; Shin T; Biorac T; Ryder NS; Goldberg R; Doughty J; He Y
Bioorg Med Chem Lett; 2004 Mar; 14(6):1477-81. PubMed ID: 15006385
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic potential of peptide deformylase inhibitors.
Chen D; Yuan Z
Expert Opin Investig Drugs; 2005 Sep; 14(9):1107-16. PubMed ID: 16144495
[TBL] [Abstract][Full Text] [Related]
39. Proteomic study of peptide deformylase inhibition in Streptococcus pneumoniae and Staphylococcus aureus.
Wang W; White R; Yuan Z
Antimicrob Agents Chemother; 2006 May; 50(5):1656-63. PubMed ID: 16641432
[TBL] [Abstract][Full Text] [Related]
40. Structure-based design of a macrocyclic inhibitor for peptide deformylase.
Hu X; Nguyen KT; Verlinde CL; Hol WG; Pei D
J Med Chem; 2003 Aug; 46(18):3771-4. PubMed ID: 12930137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
